Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
NCT05146219
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
29
Enrollment
INDUSTRY
Sponsor class
Conditions
NSCLC
EGFR Activating Mutation
Brain Metastases
Leptomeningeal Metastasis
Interventions
DRUG:
TY-9591 Tablets
Sponsor
TYK Medicines, Inc